Loading Events

Upcoming Events › Grant

Events Search and Views Navigation

Event Views Navigation

July 2021

ADDF-Harrington Scholar Program

July 30

Sponsor: Alzheimer’s Drug Discovery Foundation
LOI due date:  April 23rd, 2021, 5:00 PM EDT
Full Application due date: July 30th, 2021, 5:00 PM EDT
Award: Up to $600,000 over 2 years with dedicated support from a team of industry veterans with capabilities that include medicinal chemistry, pharmacology & toxicology, and business development. The ADDF-Harrington Scholar Program is dedicated to advancing academic discoveries into medicines for Alzheimer’s disease and related dementias.

Find out more »

Cycle 1: Alzheimer’s Drug Discovery Foundation

July 30
|Recurring Event (See all)

One event on December 3, 2021 at 12:00 am

LOI Due Dates:

  • Cycle 1: May 28, 2021
  • Cycle 2: October 1, 2021

Full Proposal Deadlines:

  • Cycle 1: July 30, 2021
  • Cycle 2: December 3, 2021

Drug Development Program
The goal of this RFP is to develop therapeutics for Alzheimer’s disease and related dementias. This RFP focuses on building preclinical evidence in animal models and on advancing lead molecules to the clinical candidate selection stage. Average Award: Up to $600,000 based on stage and scope of research.
Program to Accelerate Clinical Trials (PACT)
The goal of this RFP is to increase the number of innovative pharmacologic interventions tested in clinical studies for Alzheimer’s disease and related dementias. Average Award: Up to $3,000,000 based on stage and scope of research. For studies requiring additional support, co-funding from other funding agencies or investors is encouraged.
Neuroimaging and CSF Biomarker Development Prgram
The aim of this RFP is to develop biomarkers for which there is a clear clinical need in Alzheimer’s disease and related dementias. Average award: Up to $600,000 based on stage and scope of research.
Prevention Beyond the Pipeline
The ADDF seeks to support comparative effectiveness research, prevention clinical trials, and epidemiological studies that probe whether the use or choice of drugs alters the risk for dementia or cognitive decline. Average awards: $50,000-$100,000 for epidemiological analyses, and u to $3,000,000 for clinical trials based on stage and scope of research.

Find out more »

August 2021

Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)

August 10
|Recurring Event (See all)

One event on February 9, 2022 at 12:00 am

Sponsor: National Institutes of Health (multiple Institutes)
LOI Due Dates: 30 days before deadline
Due Date: August 10, 2021, February 9, 2022
Award: Application budgets are not limited but must reflect the actual needs of the proposed project. Applicants should rarely exceed up to $500,000 total cost per year for Phase I and up to $1,500,000 total cost per year for the Phase II. The Blueprint Neurotherapeutics Network (BPN) encourages applications from small businesses seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN are responsible for conducting all studies that involve disease- or target-specific assays, models, and other research tools and receive funding for all activities to be conducted in their own laboratories.

Find out more »

October 2021

NIH R21, R03

October 16
|Recurring Event (See all)

One event on February 16, 2021 at 12:00 am

One event on October 16, 2021 at 12:00 am

Sponsor: National Institute of Health 
DUE DATES: 

  • Cycle 3: October 16, 2020 by 5 PM of local organization time
  • Cycle 1: February 16, 2021 by 5 PM of local organization time
  • Cycle 2: June 16, 2021 by 5 PM of local organization time

Biobehavioral and Technological Interventions to Attenuate Cognitive Decline in Individuals with Cognitive Impairment or Dementia: 
The combined budget for direct costs for the two-year project period may not exceed $275,000.  No more than $200,000 may be requested in any single year.
Small Research Grants for Analyses of Gabriella Miller Kids First Pediatric Research Data (R03 Clinical Trial Not Allowed)
The combined budget for direct costs for the two year project period may not exceed $200,000.
Biobehavioral and Technological Interventions to Attenuate Cognitive Decline in Individuals with Cognitive Impairment or Dementia (R21)
The combined budget for direct costs for the two-year project period may not exceed $275,000.  No more than $200,000 may be requested in any single year.
Chronic Condition Self-Management in Children and Adolescents (R21 Clinical Trial Optional)
Direct costs are limited to $275,000 over an R21 two-year period, with no more than $200,000 in direct costs allowed in any single year.

Find out more »

December 2021

Cycle 1: Alzheimer’s Drug Discovery Foundation

December 3
|Recurring Event (See all)

One event on December 3, 2021 at 12:00 am

LOI Due Dates:

  • Cycle 1: May 28, 2021
  • Cycle 2: October 1, 2021

Full Proposal Deadlines:

  • Cycle 1: July 30, 2021
  • Cycle 2: December 3, 2021

Drug Development Program
The goal of this RFP is to develop therapeutics for Alzheimer’s disease and related dementias. This RFP focuses on building preclinical evidence in animal models and on advancing lead molecules to the clinical candidate selection stage. Average Award: Up to $600,000 based on stage and scope of research.
Program to Accelerate Clinical Trials (PACT)
The goal of this RFP is to increase the number of innovative pharmacologic interventions tested in clinical studies for Alzheimer’s disease and related dementias. Average Award: Up to $3,000,000 based on stage and scope of research. For studies requiring additional support, co-funding from other funding agencies or investors is encouraged.
Neuroimaging and CSF Biomarker Development Prgram
The aim of this RFP is to develop biomarkers for which there is a clear clinical need in Alzheimer’s disease and related dementias. Average award: Up to $600,000 based on stage and scope of research.
Prevention Beyond the Pipeline
The ADDF seeks to support comparative effectiveness research, prevention clinical trials, and epidemiological studies that probe whether the use or choice of drugs alters the risk for dementia or cognitive decline. Average awards: $50,000-$100,000 for epidemiological analyses, and u to $3,000,000 for clinical trials based on stage and scope of research.

Find out more »

ANGEL (Advanced Neurotherapeutic Grant of Excellence) Award

December 31

Sponsor: International Rett Syndrome Foundation (IRSF)
Due Date: Applications accepted on a rolling basis
Award: Up to $600,000 over two years. Grant awards must be comprised of very specific programs that are focused on pre-clinical drug discovery and development or clinical testing of therapeutic candidates.

Find out more »

Rolling Basis: Alzheimer’s Drug Discovery Foundation

December 31

PROPOSALS ACCEPTED ON A ROLLING BASIS
ADDF/NIH
Supports NIA and NINDS grant proposals in NIH format that were scored but not funded, which fall within our mission and research priorities.
Conference Funding
Supports scientific conferences that are relevant to our mission with grants up to $10,000.

Find out more »

February 2022

Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)

February 9, 2022
|Recurring Event (See all)

One event on February 9, 2022 at 12:00 am

Sponsor: National Institutes of Health (multiple Institutes)
LOI Due Dates: 30 days before deadline
Due Date: August 10, 2021, February 9, 2022
Award: Application budgets are not limited but must reflect the actual needs of the proposed project. Applicants should rarely exceed up to $500,000 total cost per year for Phase I and up to $1,500,000 total cost per year for the Phase II. The Blueprint Neurotherapeutics Network (BPN) encourages applications from small businesses seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN are responsible for conducting all studies that involve disease- or target-specific assays, models, and other research tools and receive funding for all activities to be conducted in their own laboratories.

Find out more »
+ Export Events